X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES DR. REDDYS LAB JUBILANT LIFE SCIENCES/
DR. REDDYS LAB
 
P/E (TTM) x 28.2 29.9 94.3% View Chart
P/BV x 5.8 2.9 197.6% View Chart
Dividend Yield % 0.3 0.9 34.1%  

Financials

 JUBILANT LIFE SCIENCES   DR. REDDYS LAB
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
DR. REDDYS LAB
Mar-17
JUBILANT LIFE SCIENCES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1873,397 5.5%   
Low Rs652,560 2.5%   
Sales per share (Unadj.) Rs364.3856.5 42.5%  
Earnings per share (Unadj.) Rs6.878.0 8.8%  
Cash flow per share (Unadj.) Rs24.5139.9 17.5%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %2.40.7 354.7%  
Book value per share (Unadj.) Rs164.9739.8 22.3%  
Shares outstanding (eoy) m159.28165.74 96.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.33.5 9.9%   
Avg P/E ratio x18.438.2 48.2%  
P/CF ratio (eoy) x5.121.3 24.1%  
Price / Book Value ratio x0.84.0 19.0%  
Dividend payout %43.825.7 170.8%   
Avg Mkt Cap Rs m20,061493,632 4.1%   
No. of employees `0006.222.7 27.3%   
Total wages/salary Rs m11,05231,068 35.6%   
Avg. sales/employee Rs Th9,383.06,259.0 149.9%   
Avg. wages/employee Rs Th1,786.91,369.8 130.4%   
Avg. net profit/employee Rs Th176.3569.7 30.9%   
INCOME DATA
Net Sales Rs m58,034141,961 40.9%  
Other income Rs m1911,715 11.1%   
Total revenues Rs m58,224143,676 40.5%   
Gross profit Rs m5,78624,722 23.4%  
Depreciation Rs m2,81210,266 27.4%   
Interest Rs m3,237634 510.6%   
Profit before tax Rs m-7215,537 -0.5%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6962,965 23.5%   
Profit after tax Rs m1,09012,921 8.4%  
Gross profit margin %10.017.4 57.3%  
Effective tax rate %-965.919.1 -5,061.3%   
Net profit margin %1.99.1 20.6%  
BALANCE SHEET DATA
Current assets Rs m29,28096,837 30.2%   
Current liabilities Rs m38,91284,199 46.2%   
Net working cap to sales %-16.68.9 -186.4%  
Current ratio x0.81.2 65.4%  
Inventory Days Days8473 115.0%  
Debtors Days Days5198 51.9%  
Net fixed assets Rs m55,712102,552 54.3%   
Share capital Rs m155829 18.6%   
"Free" reserves Rs m20,968121,792 17.2%   
Net worth Rs m26,265122,621 21.4%   
Long term debt Rs m17,1695,449 315.1%   
Total assets Rs m88,606218,165 40.6%  
Interest coverage x1.025.5 3.8%   
Debt to equity ratio x0.70 1,471.0%  
Sales to assets ratio x0.70.7 100.7%   
Return on assets %4.96.2 78.6%  
Return on equity %4.210.5 39.4%  
Return on capital %11.612.9 89.7%  
Exports to sales %37.854.6 69.2%   
Imports to sales %16.59.4 176.3%   
Exports (fob) Rs m21,93377,520 28.3%   
Imports (cif) Rs m9,56713,274 72.1%   
Fx inflow Rs m22,00481,670 26.9%   
Fx outflow Rs m11,74926,355 44.6%   
Net fx Rs m10,25555,315 18.5%   
CASH FLOW
From Operations Rs m8,02621,444 37.4%  
From Investments Rs m-1,744-18,404 9.5%  
From Financial Activity Rs m-4,447-3,692 120.5%  
Net Cashflow Rs m1,834-1,144 -160.4%  

Share Holding

Indian Promoters % 45.6 25.5 178.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.4 161.1%  
FIIs % 21.2 35.3 60.1%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.1 15.3 137.9%  
Shareholders   23,815 75,885 31.4%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 22, 2018 09:01 AM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS